Arca
Skip to content
Tools
Tools

Atrial fibrillation

Drug research and approvals for atrial fibrillation: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 518 studies of atrial fibrillation are recruiting on ClinicalTrials.gov, Health Canada has authorized 41 drug trials for it since 2013, FDA has 1 approved and 1 open orphan designations naming it, and the EU has 5 authorised medicines for it.

  • Recruiting worldwide: 518
  • Trials authorized in Canada: 41
  • FDA orphan approvals: 1
  • EU medicines: 5

Recruiting now

Newest posted first, of 518 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 13

Phase 3 12 of 54

Phase 2 12 of 35

Phase 1 or earlier 4

How its trials ended

3,474 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 720 whose ending is known, 46% met their primary endpoint, 8% missed it and 45% stopped early.

  • Completed, result not reported1,29437%
  • Ongoing84124%
  • Status unknown61918%
  • Met its primary endpoint33310%
  • Stopped: other or unclear1615%
  • Stopped: enrollment or feasibility1033%
  • Missed its primary endpoint602%
  • Stopped: sponsor or business decision351%
  • Stopped: lack of efficacy16<1%
  • Stopped: funding8<1%
  • Stopped: safety4<1%

Trials authorized in Canada

The 10 newest of 41; search them all in Canada trials
Jul 2, 2026A master protocol for a phase 3, randomized, multicenter, double-blind study to assess stroke and systemic embolism prevention with REGN7508 and REGN9933,…REGN7508 / REGN9933RegeneronOngoing
Sep 11, 2025A phase 2, randomized, multicenter, open-label, blinded-endpoint study to evaluate the safety of REGN7508 and REGN9933, monoclonal antibodies against fxi,…REGN7508 / REGN9933RegeneronOngoing
Jul 3, 2025A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden (AFB) as well as…PKN605Novartis PharmaceuticalsOngoing
Mar 5, 2025Multi-center, placebo-controlled, phase 3 study of etripamil nasal spray (NS) in patients with atrial fibrillation and rapid ventricular rate (RVR)Etripamil (MSP-2017)Milestone PharmaceuticalsOngoing
Jul 26, 2023Start-poaf -short term anti-arrhythmic therapy for post-operative af in cardiac surgery patients (start-poaf) pilot trialAmiodaroneHamilton Health Sciences CorporationOngoing
May 10, 2023A phase 3, randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian, an oral factor xia…Milvexian (JNJ-70033093; BMS-986177) / ApixabanJohnson & JohnsonOngoing
Apr 20, 2023Use of magnesium prophylaxis for the prevention of atrial fibrillation in critically ill patients : atomic pilot studyMagnesiumKingston Health Science CentreOngoing
Jan 19, 2023A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of abelacimab in high-risk…Abelacimab (MAA868)Anthos Therapeutics, Inc.Ongoing
Nov 3, 2022A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, phase 3 study to compare the…Asundexian (bay 2433334)BayerClosed
Jun 1, 2022A phase 3, randomized, double-blind, placebo-controlled trial of flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial…Flecainide (FLECIH-103)InCarda TherapeuticsClosed

FDA orphan designations

Approved first, then open designations, newest first
Jul 2, 2009So-AqueousFor use as a substitute for oral sotalol in patients who are unable to take sotalol orally [oral sotalol is indicated for maintenance of…AltaThera Pharmaceuticals LLCApproved
Mar 7, 2019TecarfarinPrevention of systemic thromboembolism of cardiac origin in patients with End Stage Renal Disease and atrial fibrillationCadrenal Therapeutics, Inc.Designated

Medicines authorised in the EU

Newest first
Jul 23, 2020Apixaban AccordApixaban · genericAccord Healthcare S.L.U.EMA ↗
Apr 19, 2017RoteasEdoxabanBerlin-Chemie AGEMA ↗
Jun 19, 2015LixianaEdoxabanDaiichi Sankyo Europe GmbHEMA ↗
Sep 1, 2010BrinavessVernakalant hydrochlorideAdvanz Pharma LimitedEMA ↗
Nov 25, 2009MultaqDronedaroneSanofi Winthrop IndustrieEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.